Solventum Q2 Earnings Call Highlights
Key Points
- Interested in Solventum Corporation? Here are five stocks we like better.
- Second-quarter results exceeded expectations: Sales reached $2.2 billion, with organic growth of 9.5%, while adjusted performance benefited from advanced ERP-related orders and a $100 million tariff refund. Excluding those benefits, organic growth was approximately 4% and EPS was estimated at $1.73.
- Solventum raised its 2026 outlook: The company now expects 2.5%–3% organic sales growth, a 22.2%–22.7% operating margin, adjusted EPS of $7.10–$7.20 and free cash flow of $200 million–$300 million. Third-quarter growth is expected to decline temporarily as roughly $125 million of advanced orders reverse.
- The company is pursuing a separation of Health Information Systems: Solventum is evaluating a spin-off or sale to sharpen its focus on MedSurg and Dental, while citing HIS’s growth potential in AI-driven coding and international markets.
Solventum (NYSE:SOLV) reported second-quarter results that exceeded its internal expectations, supported by broad-based segment performance, planned order activity ahead of an ERP cutover and a tariff refund benefit. The company also announced plans to separate its Health Information Systems, or HIS, business as part of a broader effort to sharpen its focus on medical technology markets.
Chief Executive Officer Bryan Hanson said the company delivered ahead of plan on both revenue and earnings, citing specialized commercial teams, product innovation and operating discipline. He said the company remains on track to achieve its long-range plan earlier than originally expected.
“The quarter came in ahead of plan, top and bottom line,” Hanson said. “Organic growth and EPS were both ahead of expectations.”
Revenue Growth Included ERP-Related Advanced Orders
Second-quarter sales totaled $2.2 billion, rising 9.5% organically from a year earlier and 2.2% on a reported basis. Foreign exchange added 100 basis points to reported growth, while acquisitions and divestitures reduced reported growth by 830 basis points, primarily due to the sale of the Purification Filtration business. The impact was partly offset by the Acera acquisition.
Chief Financial Officer Wayde McMillan said revenue growth was primarily volume-driven and included approximately $125 million of customer orders advanced ahead of the company’s North America ERP cutover. These orders are expected to mostly reverse in the third quarter.
On a normalized basis, excluding the ERP-related timing effect, SKU rationalization headwinds and a partial separation timing benefit, Solventum estimated organic sales growth at about 4% for the quarter. Pricing remained within the company’s expected range of plus or minus 1%.
- MedSurg: Sales were $1.4 billion, with organic growth of 8.9%. ERP advanced orders accounted for roughly 700 basis points of growth, primarily in Infection Prevention and Surgical Solutions.
- Dental Solutions: Sales were $396 million, with organic growth of 15.2%. Advanced orders contributed about 10 percentage points of growth, while new product launches supported underlying performance.
- Health Information Systems: Sales were $354 million, with organic growth of 5.4%, driven by revenue cycle management solutions, customer retention and commercial execution.
Hanson said Solventum has not experienced the market softness or procedure-volume pressure cited by some healthcare companies. He said the company continues to see favorable conditions across MedSurg, Dental and HIS, although management is monitoring broader industry trends.
Margins and Earnings Benefited From Tariff Refund
Gross margin rose 410 basis points year over year to 60.1%, including a one-time $100 million tariff refund. Excluding that refund, gross margin would have been approximately 55.6%, or 40 basis points below the prior-year level. McMillan attributed the decline to tariff and inflation headwinds, partly offset by savings programs and portfolio optimization.
Operating income was $627 million and operating margin was 28.4%. Excluding the effects of advanced-order timing and the tariff refund, the operating margin would have been approximately 21.7%, slightly above the high end of the company’s initial full-year outlook.
Solventum reported earnings per share of $2.55. That result included a $0.34 benefit from advanced orders and a $0.48 benefit from expected tariff refunds. Excluding those items, management estimated EPS would have been $1.73, ahead of its expectations.
The company also recorded $157 million in litigation costs related to $204 million in estimated legal charges, net of $55 million in insurance proceeds received to date. Those costs were excluded from the company’s non-GAAP operating income and EPS measures.
Solventum generated $144 million in free cash flow during the quarter, aided by the timing of tax payments and insurance proceeds. It ended the period with $403 million in cash and equivalents and net debt of $4.7 billion. During the quarter, the company repurchased nearly 4 million shares for $288 million, bringing first-half repurchases to 4.8 million shares for $355 million.
Company Pursues Separation of HIS Business
Solventum said it is advancing the separation of its Health Information Systems business, which provides healthcare technology and revenue cycle management solutions. Hanson said the company believes HIS could create more value as an independent business or as part of a larger healthcare information technology company.
Management said the unit’s financial profile is resilient and that it has growth opportunities in artificial intelligence-driven autonomous coding and international expansion. However, Hanson said the business has a different operating model from Solventum’s other operations and has limited integration with the company’s MedSurg and Dental segments.
The company has not selected a transaction structure. Hanson said management is considering alternatives including a spin-off or a sale, with the goal of maximizing shareholder value. He said Solventum has received inbound interest in the business over time and expects a broad range of parties may be interested following the public announcement.
Management expects to provide updates on the potential financial effects of the HIS separation at a later date. The company’s 2026 outlook continues to include the HIS segment.
Following the previously announced Purification Filtration divestiture and a potential HIS separation, Solventum expects to operate as a more focused med-tech company centered on MedSurg and Dental. Hanson said the company will continue to evaluate portfolio optimization opportunities but sees both remaining segments as central to its medical technology strategy.
Outlook Raised as Separation Work Nears Completion
Solventum raised and tightened its 2026 outlook. The company now expects organic sales growth of 2.5% to 3%, excluding an anticipated 100-basis-point impact from SKU exits. On an ex-SKU basis, the forecast represents growth of 3.5% to 4%.
The company increased its expected operating margin range to 22.2% to 22.7%, up from 21% to 21.5%, reflecting the full expected benefit from tariff refunds. Solventum raised its adjusted EPS outlook to $7.10 to $7.20, from $6.40 to $6.60, and now expects free cash flow of $200 million to $300 million.
McMillan said third-quarter growth is expected to be affected by the reversal of the $125 million in advanced orders, with organic sales growth anticipated in the negative 3% to negative 4% range. The company expects fourth-quarter growth to return to the positive 3% to 4% range, resulting in approximately flat growth for the second half of the year after accounting for the timing effect.
Separately, Solventum said it has exited nearly 70% of approximately 200 transition service agreements related to its separation from 3M and has migrated roughly 950 of 1,200 systems. The company remains on track to exit 90% of transition service agreements by the end of 2026.
Management expects separation-related cash demands to begin declining in the fourth quarter. Hanson said completing the ERP and separation work should allow Solventum to redirect more resources toward growth drivers, product development, savings initiatives and margin expansion.
About Solventum (NYSE:SOLV)
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Where Should You Invest $1,000 Right Now?
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
Source MarketBeat
